- Home
- VSTA vs RIGL Comparison
VSTA vs RIGL Comparison
Compare VSTA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTA
- RIGL
- Stock Information
- Founded
- VSTA 1966
- RIGL 1996
- Country
- VSTA Brazil
- RIGL United States
- Employees
- VSTA N/A
- RIGL N/A
- Industry
- VSTA Other Consumer Services
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- VSTA Real Estate
- RIGL Health Care
- Exchange
- VSTA Nasdaq
- RIGL Nasdaq
- Market Cap
- VSTA 332.9M
- RIGL 335.5M
- IPO Year
- VSTA 2020
- RIGL 2000
- Fundamental
- Price
- VSTA $4.29
- RIGL $36.58
- Analyst Decision
- VSTA Sell
- RIGL Buy
- Analyst Count
- VSTA 1
- RIGL 5
- Target Price
- VSTA N/A
- RIGL $38.20
- AVG Volume (30 Days)
- VSTA 10.3K
- RIGL 583.4K
- Earning Date
- VSTA 08-06-2025
- RIGL 08-05-2025
- Dividend Yield
- VSTA N/A
- RIGL N/A
- EPS Growth
- VSTA N/A
- RIGL N/A
- EPS
- VSTA 1.09
- RIGL 5.43
- Revenue
- VSTA $313,466,268.00
- RIGL $267,921,000.00
- Revenue This Year
- VSTA $13.97
- RIGL $14.41
- Revenue Next Year
- VSTA $10.85
- RIGL $15.97
- P/E Ratio
- VSTA $3.96
- RIGL $6.73
- Revenue Growth
- VSTA 8.99
- RIGL 105.62
- 52 Week Low
- VSTA $1.60
- RIGL $11.22
- 52 Week High
- VSTA $5.49
- RIGL $37.62
- Technical
- Relative Strength Index (RSI)
- VSTA 58.58
- RIGL 91.89
- Support Level
- VSTA $3.89
- RIGL $20.28
- Resistance Level
- VSTA $4.30
- RIGL $21.41
- Average True Range (ATR)
- VSTA 0.18
- RIGL 1.77
- MACD
- VSTA 0.02
- RIGL 1.54
- Stochastic Oscillator
- VSTA 92.94
- RIGL 94.06
About VSTA Vasta Platform Limited
Vasta Platform Ltd operates as an education company in Brazil, engaged in providing end-to-end educational and digital solutions that cater to all needs of private schools operating in the K-12 educational segment. Its business segments are Content and EdTech Platform, and Digital Platform. The Content and EdTech platform derives its results from educational content solutions through digital and printed content, including textbooks, learning systems and other complementary educational services. The Digital Platform enables private schools to aggregate multiple learning strategies and helps them to focus on education through the Business' physical and digital e-commerce platform and other digital services.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.